Publications by authors named "Laure-Amelie de Monteynard"
Background: Achieving the UNAIDS 95% sustained viral suppression (VS) rate requires considerable global efforts, particularly among adolescents living with HIV (ALHIV) who are often associated with high rates of virological failure (VF). In this study, we prospectively assessed the rate of VS, and the factors associated with VF in a cohort of adolescents followed up according to the WHO guidelines in Cameroon.
Methods: A cross-sectional study was carried out in 2021 among adolescents (aged 10-19 years) receiving ART in the national program in Cameroon.
Aims: In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system.
View Article and Find Full Text PDFImplementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
Lancet HIV
November 2019
Background: The decision about whether to switch to third-line antiretroviral therapy (ART) in patients with treatment failure on second-line therapy is difficult in settings with little access to genotypic resistance testing. In this study, we used a standardised algorithm including a wide range of adherence-enhancing interventions followed by a new viral load measurement to decide whether to switch to third-line therapy in this situation. The decision, made on the basis of effectiveness of the adherence reinforcement to drive viral resuppression, did not use genotypic resistance testing.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the impact of geographic origin on the risk of severe illness and death among HIV-infected individuals on cART in France, particularly focusing on heterosexuals from different backgrounds.
- A sample of 4,930 individuals was analyzed, revealing that male migrants from sub-Saharan Africa (SSA) and female migrants from SSA and non-French West-Indies (NFW) had a significantly higher risk of non-AIDS infections compared to French natives.
- The results suggest a need for targeted interventions to prevent infectious diseases among HIV-infected migrants, given their elevated risk of complications compared to local French populations.
Article Synopsis
- The study investigates how geographic origin, sex, and HIV transmission group impact outcomes after starting first-line combined antiretroviral therapy (cART) among HIV-1-infected adults in France from 2006 to 2011.
- It finds that migrants are more likely than French natives to start cART with low CD4 cell counts and experience poorer treatment outcomes, especially in terms of viral load undetectability and CD4 recovery.
- Nonhomosexual men, regardless of geographic origin, showed higher risks for negative health outcomes, indicating disparities in HIV management and treatment effectiveness.
Objective: To compare the time from entry into care for HIV infection until combination antiretroviral therapy (cART) initiation between migrants and non migrants in France, excluding late access to care.
Methods: Antiretroviral-naïve HIV-1-infected individuals newly enrolled in the FHDH cohort between 2002-2010, with CD4 cell counts >200/μL and no previous or current AIDS events were included. In three baseline CD4 cell count strata (200-349, 350-499, ≥ 500/μL), we examined the crude time until cART initiation within three years after enrollment according to geographic origin, and multivariable hazard ratios according to geographic origin, gender and HIV-transmission group, with adjustment for baseline age, enrollment period, region of care, plasma viral load, and HBV/HBC coinfection.